Left Ventricular Dysfunction Drug Sales

Left Ventricular Dysfunction Drug Sales Market Outlook

The global market for Left Ventricular Dysfunction (LVD) drugs is projected to reach approximately USD 28 billion by 2035, with a compound annual growth rate (CAGR) of around 6.5% during the forecast period from 2025 to 2035. This growth is attributed to the rising prevalence of cardiovascular diseases, an aging population, and advancements in drug formulations that enhance patient compliance and outcomes. Furthermore, increasing awareness about heart health and significant investments in research and development by pharmaceutical companies are fueling market expansion. The emergence of novel therapies that specifically target the underlying mechanisms of left ventricular dysfunction is also contributing to this market growth. The focus on personalized medicine and tailored treatment plans is providing additional momentum to the sales of LVD drugs in the healthcare sector.

Growth Factor of the Market

The growth of the Left Ventricular Dysfunction drug sales market can be attributed to several factors, primarily the increasing incidence of heart-related disorders across the globe. As populations age, the prevalence of conditions such as hypertension, coronary artery disease, and diabetes—which significantly contribute to left ventricular dysfunction—continues to rise. Moreover, ongoing advancements in diagnostic technologies have made it easier to identify and treat patients suffering from this condition earlier, thereby increasing the number of individuals receiving appropriate medications. Furthermore, initiatives by healthcare organizations to improve cardiovascular health awareness and promote preventive measures are expected to play a key role in market growth. The rising adoption of combination therapies that improve patient outcomes is also a notable trend driving the market forward. Additionally, new drug approvals and the expansion of existing therapies into new markets are poised to enhance the accessibility of treatment options for patients.

Key Highlights of the Market

• The global market for drugs treating left ventricular dysfunction is expected to grow significantly, driven by rising cardiovascular disease prevalence.
• Advancements in drug development, particularly with biologics and targeted therapies, play a critical role in improving patient outcomes.
• There is a growing trend of personalized medicine, enabling tailored treatment strategies for individuals based on genetic and phenotypic factors.
• The increasing integration of telehealth services in patient management is improving access to treatment and monitoring for those with heart conditions.
• Ongoing clinical trials and research are expected to uncover new therapeutic options and mechanisms of action, further diversifying the market landscape.

By Drug Type

Beta-Blockers:

Beta-blockers are one of the primary classes of medications used in the management of left ventricular dysfunction. These drugs work by blocking the effects of adrenaline on the heart, thereby decreasing heart rate and reducing cardiac workload. They have been shown to improve heart function and reduce mortality rates in patients with heart failure. The increasing adoption of beta-blockers is driven by their established efficacy in improving patient outcomes, as well as their role in managing comorbid conditions such as hypertension. Furthermore, the emergence of newer agents with improved safety profiles and fewer side effects is expected to stimulate market growth, as more healthcare providers seek to optimize treatment regimens for their patients.

ACE Inhibitors:

Angiotensin-Converting Enzyme (ACE) inhibitors play a crucial role in the treatment of left ventricular dysfunction by relaxing blood vessels and reducing blood pressure. These medications help to decrease the workload on the heart and can significantly improve symptoms and quality of life for patients with heart failure. ACE inhibitors are widely recognized for their ability to enhance survival rates by preventing the progression of heart failure. The continued focus on cardiovascular disease management and the increasing number of patients diagnosed with left ventricular dysfunction are propelling the growth of this drug segment. Additionally, ongoing research into the long-term benefits and optimal use of ACE inhibitors in various populations will likely reinforce their position in the market.

ARBs:

Angiotensin Receptor Blockers (ARBs) are another key class of drugs used to treat left ventricular dysfunction. They work by blocking angiotensin II receptors, leading to vasodilation and improved cardiac output. ARBs are particularly beneficial for patients who experience adverse reactions to ACE inhibitors, making them a valuable alternative. The growing understanding of the important role that ARBs play in heart failure management, coupled with their favorable safety profile, has led to increased prescribing rates. Moreover, efforts by pharmaceutical companies to conduct extensive clinical trials demonstrating the efficacy of ARBs in various patient populations are expected to contribute positively to the segment's growth in the coming years.

Angiotensin Receptor-Neprilysin Inhibitors:

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), a newer class of medication, have emerged as a significant advancement in the treatment of left ventricular dysfunction. By combining the effects of angiotensin receptor blockade with neprilysin inhibition, these drugs offer dual benefits in terms of improving heart function while also having neuro-hormonal protective effects. The introduction of ARNIs has reshaped the treatment landscape for heart failure, and clinical studies have shown that they can reduce the risk of hospitalization and death. As awareness of ARNIs continues to spread among healthcare providers and patients, the segment is expected to experience substantial growth, driven by their efficacy and the increasing focus on innovative treatment options.

Diuretics:

Diuretics, commonly referred to as "water pills," are pivotal in managing symptoms of left ventricular dysfunction, particularly in reducing fluid overload. They work by promoting the excretion of sodium and water, which helps to alleviate symptoms such as swelling and shortness of breath associated with heart failure. The diuretics segment remains essential due to the fact that many patients with left ventricular dysfunction experience fluid retention, necessitating the use of these medications. Additionally, the continued development of new formulations and combination therapies that enhance the effectiveness of diuretics will likely foster growth in this market segment. The increasing prevalence of heart failure and the need for comprehensive management strategies will further solidify the role of diuretics in the treatment of left ventricular dysfunction.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a critical distribution channel for drugs used in the treatment of left ventricular dysfunction. These pharmacies are responsible for providing medications to inpatients and outpatients, ensuring that patients receive appropriate therapy during their hospital stay and after discharge. The advantage of hospital pharmacies lies in their ability to offer a comprehensive range of medications, including specialized treatments that may not be available through retail pharmacies. The growing number of hospital admissions due to cardiovascular diseases is driving increased demand for medications distributed through hospital pharmacies. Furthermore, the integration of clinical pharmacists into patient care teams is enhancing medication management and optimizing therapeutic outcomes for patients with left ventricular dysfunction.

Retail Pharmacies:

Retail pharmacies represent a significant distribution channel for LVD medications, providing patients with easy access to essential drugs for managing their condition. These pharmacies typically stock a wide range of medications, including beta-blockers, ACE inhibitors, and diuretics, allowing patients to fill their prescriptions conveniently. The rise in chronic conditions and preventive care initiatives is contributing to the increased utilization of retail pharmacies for medication dispensing. Additionally, retail pharmacies frequently provide counseling and support services to patients, promoting adherence to prescribed treatments. The growing trend of pharmacy-led health services, including medication therapy management, is expected to further enhance the role of retail pharmacies in the overall distribution of LVD drugs.

Online Pharmacies:

The emergence of online pharmacies has revolutionized the way patients access medications for left ventricular dysfunction. These digital platforms offer the convenience of ordering prescriptions from the comfort of home, which is especially advantageous for patients with mobility issues or those living in remote areas. Online pharmacies typically provide competitive pricing and often have a broader selection of medications compared to traditional brick-and-mortar establishments. As telehealth services become more mainstream, the usage of online pharmacies is expected to grow significantly, facilitating medication access and improving adherence rates. However, it remains essential for patients to utilize reputable online pharmacies to ensure medication safety and quality.

By Route of Administration

Oral:

The oral route of administration is the most common method for delivering drugs used in the treatment of left ventricular dysfunction. Medications such as beta-blockers, ACE inhibitors, and diuretics are often administered orally, allowing for convenient self-administration by patients. Oral medications are generally well-accepted by patients due to their ease of use and the ability to incorporate them into daily routines. This route also allows for gradual absorption and sustained therapeutic effects. The growing focus on outpatient management and chronic disease care is further solidifying the oral route as a preferred choice for LVD medication delivery, contributing to its dominance in the market.

Intravenous:

The intravenous (IV) route of administration is typically reserved for hospitalized patients or those requiring rapid therapeutic effects, particularly in acute episodes of left ventricular dysfunction. IV medications can provide immediate relief from symptoms and are critical in managing severe cases of heart failure. The use of intravenous therapies allows for higher drug bioavailability and precise control over dosages, making it an essential approach in acute care settings. Although the IV route is less common for long-term management, its role in enhancing patient outcomes during hospitalization cannot be overstated. The ongoing development of novel intravenous therapies is expected to support growth in this segment as hospitals seek to enhance their critical care capabilities.

By Mechanism of Action

Inotropic Agents:

Inotropic agents are vital medications used in the management of left ventricular dysfunction due to their ability to increase the force of heart muscle contractions. These agents are often employed in acute heart failure situations where improved cardiac output is necessary. The effectiveness of inotropic agents stems from their ability to enhance myocardial contractility, which can significantly alleviate symptoms associated with heart failure. The increasing incidence of acute heart failure cases is expected to drive demand for inotropic agents, as healthcare providers seek to provide immediate therapeutic interventions. Ongoing research into new inotropic agents with improved safety profiles and efficacy will likely bolster this segment in the market.

Vasodilators:

Vasodilators are another critical class of medications used in the treatment of left ventricular dysfunction, primarily to reduce cardiac workload by dilating blood vessels. This mechanism leads to decreased vascular resistance, allowing the heart to pump more efficiently. Vasodilators can significantly improve symptoms of heart failure and have been shown to enhance exercise tolerance in patients. The growing recognition of the importance of managing blood pressure and improving blood flow in patients with left ventricular dysfunction is fueling the demand for vasodilators. The continued development of novel vasodilatory agents and combination therapies will likely create new opportunities for growth in this segment.

Diuretics:

As previously mentioned, diuretics play a pivotal role in the management of fluid overload associated with left ventricular dysfunction. By promoting the excretion of sodium and water, diuretics help alleviate symptoms such as edema and respiratory distress. They are a crucial component of heart failure management, particularly for patients who experience significant fluid retention. The ongoing development of new diuretic formulations and combination therapies is expected to enhance their effectiveness and tolerability. As the prevalence of heart failure increases, the demand for diuretics will continue to rise, reinforcing their importance in the overall treatment landscape.

Beta-Blockers:

Beta-blockers, as previously discussed, not only reduce heart rate but also possess a unique mechanism that protects the heart from excessive adrenaline stimulation. This mechanism is particularly beneficial for patients with left ventricular dysfunction, as it helps to reduce the risk of further heart damage or deterioration. Their effectiveness in improving heart function and reducing mortality rates has solidified their position as a cornerstone of treatment for heart failure patients. The ongoing research aimed at identifying the optimal use of beta-blockers in various patient populations will likely contribute to their sustained demand in the market, making them a reliable choice for clinicians managing left ventricular dysfunction.

Angiotensin-Converting Enzyme Inhibitors:

ACE inhibitors have a significant mechanism of action in the treatment of left ventricular dysfunction, primarily by inhibiting the conversion of angiotensin I to angiotensin II. This leads to reduced blood pressure and decreased afterload on the heart, ultimately improving cardiac output. The ability of ACE inhibitors to not only reduce symptoms but also alter the disease trajectory and improve survival rates is a major factor driving their widespread use. The increasing body of clinical evidence supporting the benefits of ACE inhibitors in various populations, coupled with the ongoing development of new agents, will bolster their presence in the market for left ventricular dysfunction medications.

By Region

The North American market for left ventricular dysfunction drugs is poised for considerable growth, driven by a high prevalence of cardiovascular diseases and robust healthcare infrastructure. The region is projected to account for approximately 40% of the global market share by 2035, with a CAGR of about 6.7% during the forecast period. The presence of key pharmaceutical companies and extensive research initiatives focused on innovative therapies are critical factors contributing to this growth. Additionally, the increasing adoption of advanced treatment options and the emphasis on managing chronic conditions will further enhance the demand for LVD drugs in this market.

Europe represents another significant market for left ventricular dysfunction drugs, expected to hold approximately 30% of the global market share by 2035. Factors such as an aging population, growing awareness of cardiovascular health, and government initiatives to improve healthcare access will drive market expansion in this region. The presence of established healthcare systems and an increasing number of clinical trials exploring new therapies will also support growth. Furthermore, the rising trend of personalized medicine and targeted treatments is expected to boost the development and sales of LVD drugs across European markets, ensuring a robust competitive landscape.

Opportunities

The opportunities for growth within the left ventricular dysfunction drug sales market are vast, particularly given the increasing prevalence of cardiovascular diseases worldwide. As healthcare providers continue to recognize the importance of early intervention and comprehensive management of heart failure, there is a growing need for effective and innovative treatment options. Pharmaceutical companies that invest in research and development to create new therapies targeting specific mechanisms of action are likely to capture significant market share. Additionally, the focus on personalized medicine, which tailors treatment plans to individual patient needs, presents an exciting opportunity for drug manufacturers to provide more effective solutions for left ventricular dysfunction, ultimately improving patient outcomes and quality of life.

Moreover, the integration of digital health technologies presents another avenue for growth within this market. The use of telemedicine and mobile health applications allows for real-time monitoring of patients, enhancing medication adherence and facilitating proactive management of heart failure symptoms. As healthcare technology continues to evolve, pharmaceutical companies that collaborate with digital health startups or invest in telehealth initiatives are likely to position themselves favorably in the competitive landscape. Furthermore, the expansion of online pharmacies and e-commerce platforms is expected to provide patients with greater access to essential medications, thereby increasing sales and market penetration of LVD drugs. Overall, the combination of innovative therapies and advancements in healthcare delivery models provides promising opportunities for market players.

Threats

Despite the promising outlook for the left ventricular dysfunction drug sales market, several threats could potentially hinder growth. One significant concern is the increasing competition posed by generics and biosimilars. As patents for many established medications begin to expire, the influx of lower-cost alternatives may lead to price erosion, impacting the profitability of branded products. Additionally, the tightening of regulatory standards and the increasing costs associated with drug development can pose challenges for pharmaceutical companies seeking to introduce new therapies into the market. The rising scrutiny over drug pricing and access to medications may also create obstacles, as healthcare providers and patients seek more affordable options.

Moreover, the potential for adverse effects or drug interactions associated with LVD medications can significantly affect patient adherence and outcomes. Concerns regarding safety profiles, especially for high-risk populations, may lead to hesitancy among healthcare providers in prescribing these medications. Furthermore, the ongoing COVID-19 pandemic has shifted the focus of healthcare resources and attention, potentially delaying clinical trials and regulatory approvals for new drugs. The dynamics of patient care and management strategies continue to evolve, meaning that pharmaceutical companies must remain agile and responsive to changing market conditions to mitigate these threats effectively.

Competitor Outlook

• Novartis AG
• Roche Holding AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AstraZeneca plc
• Sanofi S.A.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Hoffmann-La Roche Ltd.
• Servier Laboratories

The competitive landscape of the left ventricular dysfunction drug sales market is characterized by a mix of established pharmaceutical giants and emerging companies focused on innovation. Major players, such as Novartis AG, Roche Holding AG, and Pfizer Inc., have made significant investments in research and development to enhance their portfolios of cardiovascular medications. These companies are well-positioned to leverage their extensive resources and capabilities to bring novel therapies to market, ensuring a competitive edge in addressing the unmet needs of patients with left ventricular dysfunction. Furthermore, collaborations and partnerships with academic institutions, research organizations, and technology firms are common strategies employed by these companies to expedite the development of new treatments and improve patient outcomes.

Specific companies, such as Bristol-Myers Squibb and Merck & Co., are at the forefront of developing innovative therapies targeting unique mechanisms of action to enhance the management of left ventricular dysfunction. The launch of new agents, including Angiotensin Receptor-Neprilysin Inhibitors, has revolutionized treatment options, providing effective alternatives for patients who have not responded well to traditional therapies. These companies are actively conducting clinical trials to further explore the efficacy and safety profiles of their products, ensuring they remain leaders in the cardiovascular space. Their commitment to advancing research in heart failure management positions them favorably in a competitive market where patient needs continue to evolve.

In addition to established companies, several emerging biotechnology firms are focusing on niche areas within the left ventricular dysfunction market. These firms often prioritize developing targeted therapies that exploit novel pathways in cardiac physiology, paving the way for groundbreaking treatment options. For instance, companies like Amgen and Sanofi are exploring gene therapy and regenerative medicine approaches to address left ventricular dysfunction at its source. The growing interest in personalized medicine further emphasizes the need for these innovative solutions, providing opportunities for smaller firms to carve out their presence in the market alongside industry giants.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Servier Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hoffmann-La Roche Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Left Ventricular Dysfunction Drug Sales Market, By Drug Type
    • 6.1.1 Beta-Blockers
    • 6.1.2 ACE Inhibitors
    • 6.1.3 ARBs
    • 6.1.4 Angiotensin Receptor-Neprilysin Inhibitors
    • 6.1.5 Diuretics
  • 6.2 Left Ventricular Dysfunction Drug Sales Market, By Mechanism of Action
    • 6.2.1 Inotropic Agents
    • 6.2.2 Vasodilators
    • 6.2.3 Diuretics
    • 6.2.4 Beta-Blockers
    • 6.2.5 Angiotensin-Converting Enzyme Inhibitors
  • 6.3 Left Ventricular Dysfunction Drug Sales Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies
  • 6.4 Left Ventricular Dysfunction Drug Sales Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Intravenous

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Left Ventricular Dysfunction Drug Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Left Ventricular Dysfunction Drug Sales market is categorized based on

By Drug Type

• Beta-Blockers
• ACE Inhibitors
• ARBs
• Angiotensin Receptor-Neprilysin Inhibitors
• Diuretics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Route of Administration

• Oral
• Intravenous

By Mechanism of Action

• Inotropic Agents
• Vasodilators
• Diuretics
• Beta-Blockers
• Angiotensin-Converting Enzyme Inhibitors

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Roche Holding AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• AstraZeneca plc
• Sanofi S.A.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Hoffmann-La Roche Ltd.
• Servier Laboratories